Welcome to NLS Pharmaceutics
We are seeking to design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are seeking to create new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.
Press Room
Interview with Alex Zwyer, CEO of NLS Pharmaceutics Ltd. (NLS) at The London Stock Exchange Studios. You can see more info of NLS Pharmaceutics on the media in our Press Room section
Adare Pharmaceuticals and NLS Pharmaceutics collaborate to develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy
NLS Pharmaceutics Ltd. Announces Notice of Allowance of a new U.S. Patent Covering Attention Deficit Hyperactivity Disorder strengthening the scope of NLS’ Patent Portfolio.
NLS Pharmaceutics Ltd. (NLS) Announces a Reexamination Certificate by the USPTO Further Strengthening their ADHD Use Patent Validity
NLS Pharmaceutics Ltd. (NLS) Announces Notice of Allowance of two new Patents in North America Covering Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy further bolstering its Patent Portfolio
Contact us
NLS Pharmaceutics is very interested in hearing from you. Please find general contact information below.
NLS PHARMACEUTICS GROUP
Alter Postplatz 2
CH-6370 Stans NW
Switzerland
T: +41 41 618 80 00
F: +41 41 618 80 09
askus@nls-pharma.com
